Tumor progression can be affected by various cellular components of tumor cells and/or by tumor microenvironmental factors. The tumor microenvironment comprises a variety of nonmalignant stromal cells and inflammatory cytokines, which are pivotal in tumor promotion and progression. The transforming growth factor-β (TGF-β) ligands (TGF-β1, 2 and 3) are secreted inflammatory cytokines, which are known to be involved in various aspects of tumor development through two transmembrane serine-threonine kinase receptors, TGFβR1 and TGFβR2. TGF-β promotes or inhibits tumorigenesis depending on the concurrent gene mutations and tissue microenvironment present through the small mothers against decapentaplegic (Smad) and non-Smad pathways. This review aims to provide a comprehensive overview of the role of the TGF-β pathway in tumor initiation and progression.
Transforming growth factor-β (TGF-β) signaling forms a complex web in the progression of cancer. There is substantial evidence indicating that downregulated TGF-β signaling in tumor initiation. However, in certain tumors, TGF-β appears to have the ability to exert a tumor-promoting effect depending on cellular context (1–3). Accordingly, TGF-β signaling has been considered as a tumor suppressor and a promoter of tumor progression (4,5). It acts as a tumor suppressor by inhibiting cell proliferation through repressing the expression of c-Myc and certain cyclin-depenent kinase inhibitors (CDKIs) and through the secretion of anti-angiogenic factors (6,7). It functions as a tumor promoter through the stimulation of matrix deposition, perturbation of immune function and induction of epithelial-mesenchymal transition (EMT) (8). The TGF-β super-family is a large group of structurally associated proteins including TGF-β, nodal, activin, lefty, bone morphogenetic proteins and growth and differentiation factor. There are numerous cellular context-dependent factors tightly implicated in the balance of TGF-β signaling, thus TGF-β signaling forms a complicated network in cancer cells (5).
TGF-β signaling pathways
TGF-β signaling is transduced through Smad and non-Smad pathways. These pathways are mediated by TGF-β ligands, type1 and type2 receptors and Smad or non-Smad proteins, including Akt, extracellular signal-regulated kinase (ERK)1/2 and p38 mitogen-activated protein kinase (MAPK; Fig. 1). In mammals, there are three types of TGF-β (TGF-β1, 2 and 3), which are encoded by different genes and which function through the same receptor signaling systems (9). Of these, TGF-β1 is most frequently upregulated in tumor cells (10,11). However, the fate of cells following TGF-β1 treatment is often determined by cellular context and experimental conditions (12–14).
The TGF-β protein is produced as an inactive ‘latent’ high weight complex (14) and can be activated through the activity of plasminogen, which preferentially degrades the TGF-β prosegments (15,16) and through its conformational change by the metalloproteinases, matrix metalloproteinase (MMP)-9 and MMP-2 (17). There are other activation mechanisms. For example, the extracellular matrix protein, thrombospondin (18,19) and αvβ6 integrin can regulate the activity of TGF-β through a conformational change (20). Taken together, tumor cells are well equipped to activate TGF-β locally.
The effects of TGF-β signaling are mediated by three TGF-β ligands (TGF-β1-3) through TGF-β type1 (TGFβR1) and type2 receptors TGFβR2 (21–23). TGFβR1 recruits and phosphorylates receptor-regulated Smads (R-Smads) when phosphorylated. TGF-β ligands can bind to TGFβR2 with high affinity once activated by metalloproteinases. Binding of the ligands causes the formation of a heterotetrameric active receptor complex, which results in the phosphorylation of TGFβR1 by TGFβR2. The phosphorylation of R-Smads by TGFβR1 form heteromeric complexes with the common partner Smad (co-Smad; Smad4 in mammals) (17) and these R-Smads-co-Smad complexes translocate into the nucleus to regulate the expression of target genes with other DNA-binding transcription factors.
TGF-β can also activate non-canonical signaling pathways, also termed non-Smad pathways. For example, TGF-β1 is known to activate the Erk/MAPK (24,25) pathway and the phosphoinositide 3-kinase (PI3K)/Akt (26–28) pathway. These non-Smad pathways work independently or together with Smad complexes to regulate the functions of TGF-β. For example, the activation of Akt signaling by TGF-β1 has been shown to promote cell proliferation (28). TGF-β receptors activate MMPs, p38MAPK and Zinc finger E-box-binding homeobox 1 (ZEB1), ZEB2, Snail and Slug, leading to EMT, which is required for cancer cell invasion and metastasis. TGF-β can also regulate target gene expression through the MAPK signaling pathway (29,30).
TGF-β and cell proliferation
TGF-β can regulate cell growth, apoptosis, differentiation and fibrosis (1). There is substantial evidence suggesting that TGF-β can inhibit the proliferation of normal epithelial cells (31,32). TGF-β signaling has been reported to mediate cell-cycle progression inpancreatic β-cells by regulating the nuclear localization of CDKI, p27 (31). TGF-β signaling has also been reported to inhibit the proliferation of tumor cells in certain cases. The findings of a study by Senturk et al suggested that TGF-β induced p53-independent and p16 (Ink4a)-independent and reactive oxygen species (ROS)-dependent, senescence in hepatocellular carcinoma (HCC) cells and inhibited tumor growth (32). TGF-β was also reported to mediate galangin-induced autophagy. The induction of autophagy reflected the anti-proliferation effect of TGF-β signaling on HCC cells (33). Certain drugs, including Akbu-LAAO, an L-amino acid oxidase with apparent antibacterial activities, inhibits the growth and induces the apoptosis of HepG2 cells via the TGF-β signaling pathway (34). By contrast, TGF-β signaling may have a completely different role in cell growth. A previous study demonstrated that TGF-β1 induced the activation of Akt to promote β-catenin nuclear accumulation, which then regulated cyclin D1/c-myc gene transcription to eventually promote mouse precartilaginous stem cell proliferation (35).
TGF-β signaling is involved in the regulation of epithelial-mesenchymal transition
EMT is a key step in the progression of cancer invasion and metastasis, characterized by reduced epithelial marker and elevated mesenchymal marker expression (36,37). The EMT process is often associated with upregulation of TGF-β signaling and TGF-β drives EMT through the Smad-mediated or non-Smad-mediated reprogramming of gene expression (Fig. 2) (38). TGF-β receptors can induce the expression of ZEB1, ZEB2, Snail and Slug through the Smad pathway and mediate MMPs and p38MAPK through non-Smad pathways, which both lead to EMT (39). ROS are also important in TGF-β-induced EMT, primarily through the activation of MAPK and through subsequent ERK-directed activation of the Smad pathway in proximal tubular epithelial cells (40). TGF-β signaling not only mediates EMT, but it is also required for distant metastases. A previous study demonstrated that TGF-β in the breast cancer microenvironment promoted pulmonary metastases of breast cancer cells (41).
TGF-β and cancer stem cells
Advances in cancer stem cell (CSC) research have indicated that the TGF-β signaling pathway is essential for the maintenance of CSCs. CSCs have been reported to be responsible for the recurrence of disease following anticancer therapy (42). Certain extracellular and intracellular signals allow cancer progenitors to dynamically revert to a stem cell state. Evidence has shown that TGF-β induced the expression of CD133, a CSC marker, in liver cancer cell lines and increased tumor initiating ability in mice, compared with the milder and transient effect of interleukin-6 (43). Chanmee et al found that the over production of hyaluronan allowed cancer progenitors to revert to stem cell states via Twist and the TGF-β-Snail signaling axis (44). Furthermore, tumor-associated macrophages (TAMs) in the tumor microenvironment promoted CSC-like properties via TGF-β1-induced EMT in HCC (45). MicroRNA (miR)-106b is significantly upregulated in CD44(+) cells and the inhibition of miR-106b shows suppression of the TGF-β/Smad signaling pathway and decreases self-renewal capacity and cell invasiveness (46). These findings suggest that TGF-β signaling is associated with cancer cell stemness.
There are epigenetic differences in TGF-β signaling-related genes between cancer stem-like cells and differentiated cancer cells. It was previously reported that the methylation levels of genes coding TGF-β signaling-related proteins can regulate breast cancer stem cell differentiation (47). Evidence suggests that several members of the TGF-β pathway are targeted by long non-coding RNAs, key epigenetic mediators and this may, at least in part, explain the association between cancer cell stemness and TGF-β signaling (48). These findings may assist in the development of novel agents, which can specifically control increases and decreases in the TGF-β signaling pathway in CSCs and thereby provide a novel avenue for the prevention and treatment of malignant cancer (48).
Crosstalk between TGF-β signaling and inflammation
Acute inflammation is an essential component of the wound-healing response to stimuli. However, chronic inflammation favors the accumulation of mutations and epigenetic aberrations in normal cells, thereby promoting malignant transformation (49,50). This process is mediated by chemokines, cytokines and growth factors secreted by stromal components of the tumor microenvironment. Among those secreted factors, the TGF-β subfamily has been shown to generate a favorable immune microenvironment for tumor growth. TGF-β can impair anticancer immune responses in several ways, including immune cell inhibition and the elimination of major histocompatibility complex class I and II (51). It can also induce TAMs and generate ROS with genotoxic activity (52–54). TAMs are primarily a macrophage subpopulation with an M2 phenotype. TAM-derived factors may enhance the invasiveness of tumor cells by enhancing their adhesion to extracellular matrix in the tumor stroma (55,56). Evidence from clinical and epidemiological studies has shown that TAM density is positively associated with poor survival rates in several types of cancer (56,57). The involvement of ROS signaling in tumor progression has also been recognized (58,59). Previous studies have suggested that the increased generation of ROS in tumor cells may affect certain redox-sensitive molecules, leading to mutations and genetic instability, cellular proliferation and metastasis (60,61).
TGF-β signaling in the regulation of tumor angiogenesis
The ability of tumor cells to induce the formation of blood vessels is crucial for tumor growth, invasion and metastasis. TGF-β is a key mediator of angiogenesis in the tumor microenvironment, contributing to angiogenesis by inducing proangiogenic factors (62).
TGF-β can induce a proangiogenic environment and stimulate tumor-associated angiogenesis. Elevated expression levels of TGF-β have been linked to increased microvessel density in certain tumor types (63). The mechanism of angiogenesis stimulated by TGF-β signaling includes the induction of key angiogenic factors, including connective tissue growth factor, vascular endothelial growth factor and insulin-like growth factor-binding protein 7, in epithelial cells and fibroblasts (64,65). In addition, TGF-β can induce the expression, secretion and activation of matrix metalloproteinase 2 (MMP2) and MMP9 and down regulate the expression of tissue inhibitor of metalloproteinase in tumor and endothelial cells (66–68).
However, TGF-β also has angiostatic functions. For example, in pancreatic cancer and diffuse-type gastric cancer, TGF-β induces the production of thrombospondin1, a potent angiogenic inhibitor, whereas perturbations of TGF-β signaling resulted in accelerated angiogenesis and growth of tumors (69). Whether TGF-β is angiogenic or angiostaticis is dependent on the cellular context of tumor cells, epithelial cells and the tumor microenvironment.
Conclusion
Several lines of evidence suggest that the TGF-β family is involved in tumor initiation and progression, including cell proliferation, angiogenesis, cancer cell stemness, EMT, invasion and inflammation. TGF-β signaling is complex and mediates pro- and anti-tumoral activities in cancer cells depending on their context in space and time and their microenvironment (52). It is generally accepted that TGF-β is primarily a tumor suppressor in premalignant cells but functions as a promoter of metastasis in cancer cells (70,71). However, the mechanisms underlying the contextual changes in the role of TGF-β remain to be elucidated. Xu et al provided molecular insight into how TGF-β converts from a tumor suppressor to a tumor promoter. It was found that 14-3-3ζ turned off the tumor suppression function of TGF-β by destabilizing p53, a Smad partner in premalignant cells. By contrast, 14-3-3ζ promoted TGF-β-induced distant metastasis by stabilizing Gli family zinc finger 2 (Gli2) and inducing the partnering of Gli2 with Smads in malignant cells (70). Therefore, the 14-3-3ζ-driven contextual changes of Smad partners from p53 to Gli2 may provide therapeutic targets in TGF-β-mediated cancer progression.
Acknowledgements
This review was supported by grants from the National Natural Science Foundation of China (grant no. 81502131), The Natural Science Foundation of Chongqing (grant no. cstc2016jcyjA0405) and the Science and Technology Project of Chongqing Municipal Education Commission (grant no. KJ1500332).
AbbreviationsTGF-β
transforming growth factor-β
EMT
epithelial-mesenchymal transition
CDKIs
cyclin-dependent kinase inhibitors
PI3K
phosphoinositide 3-kinase
MAPK
mitogen-activated protein kinase
CSCs
cancer stem cells
TAMs
tumor-associated macrophages
ROS
reactive oxygen species
MMP
matrix metalloproteinase
ReferencesMorrisSMCarterKTBaekJYKoszarekAYehMMKnoblaughSEGradyWMTGF-β signaling alters the pattern of liver tumorigenesis induced by Pten inactivation3432733282201510.1038/onc.2014.25825132272HorieYSuzukiAKataokaESasakiTHamadaKSasakiJMizunoKHasegawaGKishimotoHIizukaMHepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas11317741783200410.1172/JCI2051315199412420505AttisanoLWranaJLSignal integration in TGF-β, WNT, and Hippo pathways517201310.12703/P5-17237553643672943IkushimaHMiyazonoKTGFbeta signalling: A complex web in cancer progression10415424201010.1038/nrc285320495575DerynckRAkhurstRJBalmainATGF-beta signaling in tumor suppression and cancer progression29117129200110.1038/ng1001-11711586292KiyonoKSuzukiHIMorishitaYKomuroAIwataCYashiroMHirakawaKKanoMRMiyazonoKc-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma10018091816200910.1111/j.1349-7006.2009.01248.x19594546KomuroAYashiroMIwataCMorishitaYJohanssonEMatsumotoYWatanabeAAburataniHMiyoshiHKiyonoKDiffuse-type gastric carcinoma: Progression, angiogenesis, and transforming growth factor beta signaling101592604200910.1093/jnci/djp058193519252669102RobertsABWakefieldLMThe two faces of transforming growth factor beta in carcinogenesis10086218623200310.1073/pnas.163329110012861075166359MassaguéJTGF-beta signal transduction67753791199810.1146/annurev.biochem.67.1.7539759503MassaguéJBlainSWLoRSTGFbeta signaling in growth control, cancer, and heritable disorders103295309200010.1016/S0092-8674(00)00121-511057902WangYLiuTTangWDengBChenYZhuJShenXHepatocellular carcinoma cells induce regulatory T cells and lead to poor prognosis via production of transforming growth factor-β138306318201610.1159/00043863126799063ShenHGuanDShenJWangMChenXXuTLiuLShuYTGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN7716201610.1016/j.biopha.2015.10.01826796257YoshimotoTFujitaTKajiyaMMatsudaSOuharaKShibaHKuriharaHInvolvement of smad2 and Erk/Akt cascade in TGF-β1-induced apoptosis in human gingival epithelial cells75165173201510.1016/j.cyto.2015.03.01125882870DaiCYangJLiuYTransforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling2781253712545200310.1074/jbc.M30077720012560323LyonsRMGentryLEPurchioAFMosesHLMechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin11013611367199010.1083/jcb.110.4.136121390362116088AndreasenPAKjøllerLChristensenLDuffyMJThe urokinase-type plasminogen activator system in cancer metastasis: A review72122199710.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z9212216YuQStamenkovicICell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis14163176200010652271316345MirFAContreras-RuizLMasliSThrombospondin-1-dependent immune regulation by transforming growth factor-β2-exposed antigen-presenting cells146547556201510.1111/imm.12517264584934693892Murphy-UllrichJEPoczatekMActivation of latent TGF-beta by thrombospondin-1: Mechanisms and physiology115969200010.1016/S1359-6101(99)00029-510708953DuttaALiJFedeleCSayeedASinghAVioletteSMManesTDLanguinoLRαvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression466525536201510.1042/BJ20140698255587794363118FengXHDerynckRSpecificity and versatility in tgf-beta signaling through Smads21659693200510.1146/annurev.cellbio.21.022404.14201816212511ShiYMassaguéJMechanisms of TGF-beta signaling from cell membrane to the nucleus113685700200310.1016/S0092-8674(03)00432-X12809600HeldinCHMiyazonoKten DijkePTGF-beta signalling from cell membrane to nucleus through SMAD proteins390465471199710.1038/372849393997ParkSJungHHParkYHAhnJSImYHERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression407680686201110.1016/j.bbrc.2011.03.07521440529ChengXGaoWDangYLiuXLiYPengXYeXBoth ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation2013463740201310.1155/2013/463740239368663725803YuJSRamasamyTSMurphyNHoltMKCzapiewskiRWeiSKCuiWPI3K/mTORC2 regulates TGF-β/Activin signalling by modulating Smad2/3 activity via linker phosphorylation67212201510.1038/ncomms8212259984424455068VoBTMortonDJrKomaragiriSMillenaACLeathCKhanSATGF-β effects on prostate cancer cell migration and invasion are mediated by PGE2 through activation of PI3K/AKT/mTOR pathway15417681779201310.1210/en.2012-2074235152903628025SinghaPKPandeswaraSGengHLanRVenkatachalamMASaikumarPTGF-β induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer53203362014253529494209604Reduced beta 2 glycoprotein I improve diabetic nephropathy via inhibiting TGF-β1-p38 MAPK pathway [Retraction]8197922015267706464694546ChenITHsuPHHsuWCChenNJTsengPHPolyubiquitination of transforming growth factor β-activated Kinase 1 (TAK1) at lysine 562 residue regulates TLR4-mediated JNK and p38 MAPK activation512300201510.1038/srep12300261895954507259SuzukiTDaiPHatakeyamaTHaradaYTanakaHYoshimuraNTakamatsuTTGF-β signaling regulates pancreatic β-Cell proliferation through control of cell cycle regulator p27 expression465158201310.1267/ahc.12035237206033661777SenturkSMumcuogluMGursoy-YuzugulluOCingozBAkcaliKCOzturkMTransforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth52966974201010.1002/hep.2376920583212WangYWuJLinBLiXZhangHDingHChenXLanLLuoHGalangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway326917201410.1016/j.tox.2014.09.01025268046GuoCLiuSDongPZhaoDWangCTaoZSunMZAkbu-LAAO exhibits potent anti-tumor activity to HepG2 cells partially through produced H2O2 via TGF-β signal pathway518215201510.1038/srep18215266559284677388ChengLZhangCLiDZouJWangJTransforming growth factor-β1 (TGF-β1) induces mouse precartilaginous stem cell proliferation through TGF-β receptor II (TGFRII)-Akt-β-catenin signaling151266512676201410.3390/ijms150712665250360314139866Kudo-SaitoCShirakoHTakeuchiTKawakamiYCancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells15195206200910.1016/j.ccr.2009.01.02319249678HayEDAn overview of epithelio-mesenchymal transformation154820199510.1159/0001477488714286MuthusamyBPBudiEHKatsunoYLeeMKSmithSMMirzaAMAkhurstRJDerynckRShcA protects against epithelial-mesenchymal transition through compartmentalized inhibition of TGF-β-Induced Smad activation13e1002325201510.1371/journal.pbio.1002325266805854682977XuJLamouilleSDerynckRTGF-beta-induced epithelial to mesenchymal transition19156172200910.1038/cr.2009.5191535984720263LeeJYChangJWYangWSKimSBParkSKParkJSLeeSKAlbumin-induced epithelial-mesenchymal transition and ER stress are regulated through a common ROS-c-Src kinase-mTOR pathway: Effect of imatinib mesylate300F12141222201110.1152/ajprenal.00710.201021367918PaduaDZhangXHWangQNadalCGeraldWLGomisRRMassaguéJTGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 41336677200810.1016/j.cell.2008.01.046183949902390892NakaKTGF-β signaling in cancer stem cells737847892015(In Japanese)25985631YouHDingWRountreeCBEpigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta5116351644201010.1002/hep.23544201961152862140ChanmeeTOntongPMochizukiNKongtawelertPKonnoKItanoNExcessive hyaluronan production promotes acquisition of cancer stem cell signatures through the coordinated regulation of Twist and the transforming growth factor β (TGF-β)-Snail signaling axis2892603826056201410.1074/jbc.M114.564120250779684176217FanQMJingYYYuGFKouXRYeFGaoLLiRZhaoQDYangYLuZHWeiLXTumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma352160168201410.1016/j.canlet.2014.05.00824892648YuDShinHSLeeYSLeeYCmiR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells9413701381201410.1038/labinvest.2014.12525286029El HelouRWicinskiJGuilleAAdélaïdeJFinettiPBertucciFChaffanetMBirnbaumDCharafe-JauffretEGinestierCBrief reports: A distinct DNA methylation signature defines breast cancer stem cells and predicts cancer outcome3230313036201410.1002/stem.179225069843WangJShaoNDingXTanBSongQWangNJiaYLingHChengYCrosstalk between transforming growth factor-β signaling pathway and long non-coding RNAs in cancer370296301201610.1016/j.canlet.2015.11.00726577807MartinMHercegZFrom hepatitis to hepatocellular carcinoma: A proposed model for cross-talk between inflammation and epigenetic mechanisms48201210.1186/gm307222930893334556Hernandez-GeaVToffaninSFriedmanSLLlovetJMRole of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma144512527201310.1053/j.gastro.2013.01.002233139653578068NanaAWYangPMLinHYOverview of transforming growth factor β superfamily involvement in glioblastoma initiation and progression1668136823201510.7314/APJCP.2015.16.16.681326514451NeuzilletCde GramontATijeras-RaballandAde MestierLCrosJFaivreSRaymondEPerspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas57894201410.18632/oncotarget.156924393789YangLPangYMosesHLTGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression31220227201010.1016/j.it.2010.04.002205385422891151YangLTGFbeta, a potent regulator of tumor microenvironment and host immune response, implication for therapy10374380201010.2174/15665241079131703920455854ChenJYaoYGongCYuFSuSChenJLiuBDengHWangFLinLCCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM319541555201110.1016/j.ccr.2011.02.006214817943107500PittetMJBehavior of immune players in the tumor microenvironment215359200910.1097/CCO.0b013e32831bc38a191250192901856CondeelisJPollardJWMacrophages: obligate partners for tumor cell migration, invasion and metastasis124263266200610.1016/j.cell.2006.01.00716439202StorzPReactive oxygen species in tumor progression1018811896200510.2741/166715769673RadiskyDCLevyDDLittlepageLELiuHNelsonCMFataJELeakeDGoddenELAlbertsonDGNietoMARac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability436123127200510.1038/nature03688160010732784913PelicanoHCarneyDHuangPROS stress in cancer cells and therapeutic implications797110200410.1016/j.drup.2004.01.00415158766SuhYAArnoldRSLassegueBShiJXuXSorescuDChungABGriendlingKKLambethJDCell transformation by the superoxide-generating oxidase Mox14017982199910.1038/4345910485709KalluriRBasement membranes: Structure, assembly and role in tumour angiogenesis3422433200310.1038/nrc109412778132HasegawaYTakanashiSKanehiraYTsushimaTImaiTOkumuraKTransforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma91964971200110.1002/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O11251948KangYSiegelPMShuWDrobnjakMKakonenSMCordón-CardoCGuiseTAMassaguéJA multigenic program mediating breast cancer metastasis to bone3537549200310.1016/S1535-6108(03)00132-612842083Sánchez-ElsnerTBotellaLMVelascoBCorbiAAttisanoLBernabéuCSynergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression2763852738535200110.1074/jbc.M10453620011486006ZhaoJChengQYePYangGLiuSAoQLiuYHuYAtorvastatin improves pathological changes in the aged kidney by upregulating peroxisome proliferator-activated receptor expression and reducing matrix metalloproteinase-9 and transforming growth factor-β1 levels743742201610.1016/j.exger.2015.12.00426680767HuaYZhangWXieZXuNLuYMMP-2 is mainly expressed in arterioles and contributes to cerebral vascular remodeling associated with TGF-β1 signaling59317325201610.1007/s12031-015-0687-226590999ŞekerciÇAIşbilenBIşmanFAkbalCŞimşekFTarcanTUrinary NGF, TGF-β1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia191199205201410.1016/j.juro.2013.08.02523973519Schwarte-WaldhoffIVolpertOVBouckNPSiposBHahnSAKlein-ScorySLüttgesJKlöppelGGraevenUEilert-MicusCSmad4/DPC4-mediated tumor suppression through suppression of angiogenesis9796249629200010.1073/pnas.97.17.96241094422716915XuJAcharyaSSahinOZhangQSaitoYYaoJWangHLiPZhangLLoweryFJ14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli227177192201510.1016/j.ccell.2014.11.025256700794325275AkahiraJSugihashiYSuzukiTItoKNiikuraHMoriyaTNittaMOkamuraHInoueSSasanoHDecreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: Its correlation with aberrant DNA methylation1026872693200410.1158/1078-0432.CCR-03-051015102672
TGF-β transduces signaling through the Smad and non-Smad signaling pathways. In the Smad pathway (left), TGF-β binds to TβRII, which phosphorylates TβRI, which activates Smad2 and Smad3 (R-Smads). Activated Smad2/3 forms R-Smads-co-Smad complexes with Smad4 (co-Smad), which interact with various transcription factors and transcriptional co-activators and regulates the transcription of target genes. TGF-β induces EMT through non-Smad proteins, including ZEB1/ZEB2 and Snail/Slug through the Smad pathway. In the non-Smad pathway (right), TGF-β can mediate EMT through non-Smad pathways. EMT is also mediated by extracellular signaling proteins, including Wnt, Notch ligands and PDGF. TGF-β can regulate other cellular responses with the exception of EMT, through non-Smad pathways, for example the PI3K-Akt signaling pathway and MAPK signaling. TGF-β, transforming growth factor-β; TβR, TGF-β receptor; Smad, small mothers against decapentaplegic; EMT, epithelial-mesenchymal transition; ZEB1, Zinc finger E-box-binding homeobox 1; ZEB2 Zinc finger E-box-binding homeobox 2; PDGF, platelet-derived growth factor; FGF, fibroblast growth factor; PI3K, phosphoinositide 3-kinase; MAPK, mitogen-activated protein kinase; ROS, reactive oxygen species; MMPs, matrix metalloproteinases.
TGF-β drives EMT phenotype. Exposure of tumor cells to TGF-β in situ causes certain cells to become motile and invade into neighboring blood vessels and tissues. This is accompanied by morphogenetic changes. TGF-β, transforming growth factor-β; EMT, epithelial-mesenchymal transition.